Back to Journals » Drug Design, Development and Therapy » Volume 14

Volumetric Absorptive Microsampling as a Sampling Alternative in Clinical Trials and Therapeutic Drug Monitoring During the COVID-19 Pandemic: A Review

Authors Harahap Y, Diptasaadya R, Purwanto DJ

Received 26 August 2020

Accepted for publication 17 November 2020

Published 31 December 2020 Volume 2020:14 Pages 5757—5771


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jianbo Sun

Yahdiana Harahap,1 Rasmina Diptasaadya,1 Denni Joko Purwanto2

1Faculty of Pharmacy, Universitas Indonesia, Depok, West Java 16424, Indonesia; 2Functional Medical Staff of Surgical Oncology, Dharmais Cancer Hospital, Jakarta 11420, Indonesia

Correspondence:Yahdiana Harahap
Faculty of Pharmacy, Universitas Indonesia, Pondok Cina, Beji, Depok, West Java 16424, Indonesia
Phone/ Fax +62 818222192/021
78849001-003 Email

Abstract: An infectious disease, COVID-19, caused by a new type of coronavirus, has been discovered recently. This disease can cause respiratory distress, fever, and fatigue. It still has no drug and vaccine for treatment and prevention. Therefore, WHO recommends that people should stay at home to reduce disease transmission. Due to the quarantine, FDA stated that this could hamper drug development clinical trial protocols. Hence, an alternative sampling method that can be applied at home is needed. Currently, volumetric absorptive microsampling (VAMS) has become attention in its use in clinical and bioanalytical fields. This paper discusses the advantages and challenges that might be found in the use of VAMS as an alternative sampling tool in clinical trials and therapeutic drug monitoring (TDM) during the COVID-19 pandemic. VAMS allows easy sampling, can be done at home, storage and delivery at room temperature, and the volume taken is small and minimally invasive. VAMS is also able to absorb a fixed volume that can increase the accuracy and precision of analytical methods, and reduce the hematocrit effects (HCT). The use of VAMS is expected to be implemented immediately in clinical trials and TDM during this pandemic considering the benefits it has.

Keywords: clinical trials, COVID-19, drug development, therapeutic drug monitoring, TDM, volumetric absorptive microsampling, VAMS

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]